U.S. Postpartum Depression Diagnoses Doubled in a Decade
By Ernie Mundell HealthDay Reporter
WEDNESDAY, Nov. 20, 2024 -- Rates of postpartum depression have more than doubled in little over a decade among American women, a new analysis shows.
While about 1 in every 10 new moms (9.4%) suffered postpartum depression in 2010, that number rose to almost 1 in every 5 (19%) by 2021, report a team from Kaiser Permanente Southern California.
Why the steep rise? Better detection and reporting could be playing a big role, the researchers said.
However, rising rates of obesity during pregnancy could also be a factor, since obesity has long known to be a risk factor for postpartum depression.
Whatever the reasons, "the prevalence of postpartum depression is high and rising," said a team led by Dr. Darios Getahun, a Kaiser researcher based in Pasadena, Calif. His team published its findings Nov. 20 in the journal JAMA Network Open.
As defined by the researchers, postpartum depression is "a depressive disorder that occurs within 12 months following childbirth."
Like other forms of depression, symptoms include sadness, anxiety and lack of interest in activities that were once pleasurable. Mothers with postpartum depression may fail to bond with their infant, neglect breastfeeding and develop other illnesses.
"In severe cases, postpartum depression can lead to suicide or infanticide," Getahun's team wrote in the report.
In their new analysis, the researchers tracked rates of postpartum depression for more than 442,000 California pregnancies between 2010 and 2021. The cohort of women was diverse and averaged 31 years of age at childbirth.
The researchers found a doubling of diagnosed postpartum depression rates over the study period.
Much of that might be linked to better awareness of the issue among women and their doctors.
Getahun's team pointed to newly established guidelines from the American Academy of Pediatrics (AAP) and the American College of Obstetricians and Gynecologists, which have both encouraged postpartum depression screening as part of well-child visits.
The AAP now advises screening for postpartum depression at well-child visits when a baby reaches 1-to-2, 4, and 6 months of age.
Obesity could be playing a role, as well.
By 2021, rates of postpartum depression had risen to 17% among new moms of normal weight, 19.8% among mothers deemed overweight, 21.2% among women at lower levels of obesity, and 24.2% among women with more severe obesity.
The Kaiser team noted that an uptick in postpartum depression rates has been happening alongside "a parallel increase" in obesity rates among pregnant U.S. women over the past decade.
According to Getahun's team, prior research has shown "consistently higher rates" of postpartum depression at higher body weights.
All the new findings "provide valuable insights for guiding future public health initiatives aimed at improving perinatal maternal health outcomes and promoting maternal and child well-being," the team said.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-21 06:00
Read more
- Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
- ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer
- AI Helps Spot Brain Tumor Tissue Surgeons Miss
- Incidence of Dyslipidemia Elevated During COVID-19 Pandemic
- Depression Rates on the Rise for Sexual, Gender Minority College Students
- Antiviral Treatment Underutilized for Children, Teens With Flu
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions